Risk factors

What each company says could go wrong in its 10-K, and what changed since last year: the risks added, dropped and rewritten.

7,691 annual reports · 4,011 companies

Readings are automated and can be wrong; check the filing for the exact wording.

Older filings

Page 124 of 641 · 7,691 filings

  • CuriosityStream (CURI) FY2025 10-K risk factors
    59 risks4 new3 dropped9 reworded

    CuriosityStream expanded into licensing content for AI model training and increased reliance on non-cash barter transactions. The company lost emerging growth company status but remains a smaller reporting company.

    Filed Mar 12, 2026
  • Citizens Financial Services (CZFS) FY2025 10-K risk factors
    22 risks2 new3 reworded

    The bank added risks regarding investment portfolio impairments and technological disintermediation from digital assets and blockchain.

    Filed Mar 12, 2026
  • Precision Biosciences (DTIL) FY2025 10-K risk factors
    73 risks5 new21 dropped18 reworded

    Precision BioSciences added regulatory risks covering UK clinical trials, US orphan drug designations, FDA Fast Track, and EU Health Technology Assessments.

    Filed Mar 12, 2026
  • DUKE Robotics (DUKR) FY2025 10-K risk factors
    36 risks7 new5 dropped6 reworded

    DUKE Robotics faces severe going concern doubts as cash falls short of projected twelve-month operating requirements. Operations in Israel expose the company to heightened geopolitical, military, and export control risks from the Israeli Ministry of Defense. Revenue concentration on government and energy utility customers creates vulnerability to budget delays and procurement changes.

    Filed Mar 12, 2026
  • Elicio Therapeutics (ELTX) FY2025 10-K risk factors
    90 risks13 new9 dropped28 reworded

    Elicio Therapeutics faces new risks regarding trade tariffs, early-stage clinical execution, and patent exclusivity for ELI-002.

    Filed Mar 12, 2026
  • Erasca (ERAS) FY2025 10-K risk factors
    92 risks5 new5 dropped13 reworded

    Erasca added risks covering clinical trial EU regulations, foreign trial data acceptance, BIOSECURE Act restrictions, Joyo's China activities, and AI technology deployment.

    Filed Mar 12, 2026
  • EverCommerce (EVCM) FY2025 10-K risk factors
    57 risks3 new2 dropped5 reworded

    Cybersecurity now emphasizes third-party providers, confidential data, financial penalties, and legal liability.

    Filed Mar 12, 2026
  • Filana Therapeutics (FLNA) FY2025 10-K risk factors
    99 risks10 new11 dropped16 reworded

    Filana Therapeutics shifted its primary focus from Alzheimer's disease to TSC-related epilepsy in mid-2025, following the failure of its Phase 3 Alzheimer's trials.

    Filed Mar 12, 2026
  • Funko (FNKO) FY2025 10-K risk factors
    57 risks1 new13 reworded

    Total indebtedness increased to $219.9 million as of December 31, 2025, with credit facility maturity extended to December 31, 2027.

    Filed Mar 12, 2026
  • First Northwest Bancorp (FNWB) FY2025 10-K risk factors
    38 risks13 new3 dropped9 reworded

    Executive departures in 2025 and early 2026 create significant leadership continuity risks for the bank. Large loan concentrations and nonperforming assets of $24.0 million threaten financial stability.

    Filed Mar 12, 2026
  • Fossil Group (FOSL) FY2025 10-K risk factors
    66 risks16 new10 dropped16 reworded

    Fossil added extensive risk disclosures regarding its $205.1 million indebtedness, new revolving credit facility, and springing maturity features. The company updated its fashion license expiration dates and reported persistent net losses and negative operating cash flows.

    Filed Mar 12, 2026
  • First US Bancshares (FUSB) FY2025 10-K risk factors
    37 risks1 new1 dropped5 reworded

    Digital banking trends introduced as a new risk of deposit volatility.

    Filed Mar 12, 2026

Companies covered

4,011 companies

371 more under A